

<!--StartFragment-->RESULT 5

AAM49641

ID AAM49641 standard; protein; 836 AA.

XX

AC AAM49641;

XX

DT 17-MAY-2002 (first entry)

XX

DE Human tumour-associated antigen B345 protein SEQ ID NO 4.

XX

KW Tumour-associated antigen; human; B345; cytostatic; cell communication;

KW cell interaction; signal transduction; metastasis; cancer; colon;

KW immunotherapy; carcinoma; lung; diagnosis.

XX

OS Homo sapiens.

XX

PN WO200204508-A1.

XX

PD 17-JAN-2002.

XX

PF 05-JUL-2001; 2001WO-EP007705.

XX

PR 07-JUL-2000; 2000DE-01033080.

PR 19-APR-2001; 2001DE-01019294.

XX

PA (BOEH) BOEHRINGER INGELHEIM INT GMBH.

XX

PI Schweifer N, Scherl-Mostageer M, Sommergruber W, Abseher R;

XX

DR WPI; 2002-171704/22.

DR N-PSDB; ABA99507.

XX

PT New tumor-associated antigen B345, useful for diagnosis and immunotherapy of tumors, also related nucleic acid and antibodies.

XX

PS Claim 1; Page 85-88; 102pp; German.

XX

CC This invention describes a novel tumour-associated antigen, designated
 CC B345 which has cytostatic activity. B345 is involved in communication,
 CC interaction and/or signal transduction with extracellular components and
 CC ligands, especially in the metastatic potential of cancers, particularly
 CC of the colon. B345 or its immunogenic fragments, also the DNA that
 CC encodes it, are useful for immunotherapy of cancer, particularly
 CC carcinoma of lung or colon. Antibodies raised against B345 are useful for
 CC treatment and diagnosis of cancers that are associated with B345
 CC expression, including their use for targeted delivery of cytotoxic or
 CC radioactive agents. Probes derived from B345 can be used to detect tumour
 CC -specific mutations in the B345 sequence, and can be used to screen for
 CC B345 specific modulators. This sequence represents a human B345 tumour-
 CC associated antigen described in the invention

XX

SQ Sequence 836 AA;

Query Match 99.8%; Score 4385; DB 5; Length 836;

Best Local Similarity 99.8%; Pred. No. 0;

Matches 834; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MAGLNCGVSIALLGVLLGAARLPRGAEAFEIALPRESNITVLIKLGTPDLLAKPCYIVI 60

|||||

Db 1 MAGLNCGVSIALLGVLLGAARLPRGAEAFEIALPRESNITVLIKLGTPDLLAKPCYIVI 60

Qy	61	SKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLIPT	120
Db	61	SKRHITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLIPT	120
Qy	121	LNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSN	180
Db	121	LNRTFIWDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSN	180
Qy	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Db	181	GTVSRIKMQEGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANY	240
Qy	241	PEGFPEDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDK	300
Db	241	PEGFPEDELMTWQFVVPAPHLRASVSFLNFNLSNCERKEERVEYYIPGSTTNPEVFKLEDK	300
Qy	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Db	301	QPGNMAGNFNLSLQGCDDAQSPGILRLQFQVLVQHPQNESNKIYVVDLSNERAMSLTIE	360
Qy	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVEKTISCTDH	420
Db	361	PRPVKQSRKFVPGCFVCLESRTCSSNLTLTSGSKHKISFLCDDLTRLWMNVEKTISCTDH	420
Qy	421	RYCQRKSYSLSQVPSDILHLPVELHDFSWKLLVPKDRLSLVLVPAQKLQQTKEKPCNTSF	480
Db	421	RYCQRKSYSLSQVPSDILHLPVELHDFSWKLLVPKDRLSLVLVPAQKLQQTKEKPCNTSF	480
Qy	481	SYLVASAIQSDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSFRQEASRQGLTVSFIPY	540
		:	
Db	481	SYLVASAIQSDLYFGSFCPGGSIKQIQVKQNISVTLRTFAPSFQEQEASRQGLTVSFIPY	540
Qy	541	FKEEGVFTVTPDTKSKVYLRTPNWDRGLPSLTSVSWNISVPRDQVACLTFFKERSGVVCQ	600
Db	541	FKEEGVFTVTPDTKSKVYLRTPNWDRGLPSLTSVSWNISVPRDQVACLTFFKERSGVVCQ	600
Qy	601	TGRAFMIIQEQRTAEIEIFSLDEDVLPKPSFHHHSFWVNISNCSPTSGKQLDLLFSVTLT	660
Db	601	TGRAFMIIQEQRTAEIEIFSLDEDVLPKPSFHHHSFWVNISNCSPTSGKQLDLLFSVTLT	660
Qy	661	PRTVDLTVILIAAVGGGVLLLSALGLIICCVKKKKKTKNGPAVGIYNGNINTEMPRQPK	720
Db	661	PRTVDLTVILIAAVGGGVLLLSALGLIICCVKKKKKTKNGPAVGIYNGNINTEMPRQPK	720
Qy	721	KFQKGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVDTYRPFQGTMGVCPSPPTIC	780
Db	721	KFQKGRKDNDSHVYAVIEDTMVYGHLLQDSSGSFLQPEVDTYRPFQGTMGVCPSPPTIC	780
Qy	781	SRAPTAKLATEEPPPRSPPESESEPYTFSHPNNGDVSSKDTDIPLLSTQEPMEPAE	836
		:	
Db	781	SRAPTAKLATEEPPPRSPPESESEPYTFSHPNNGDVSSKDTDIPLLNTQEPMEPAE	836

<!--EndFragment-->